about
Was it there all the time?Role of anti-C1q autoantibodies in the pathogenesis of lupus nephritis.Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome.Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab.Role of the skin biopsy in the diagnosis of atypical hemolytic uremic syndrome.Discovery and Structural Modification of 1-Phenyl-3-(1-phenylethyl)urea Derivatives as Inhibitors of Complement.Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in miceIdentification of a potent and orally active non-peptide C5a receptor antagonist.New insights of an old defense system: structure, function, and clinical relevance of the complement system.Complement and systemic lupus erythematosus.Effect of complement and its regulation on myasthenia gravis pathogenesis.Critical role of the complement system in group B streptococcus-induced tumor necrosis factor alpha release.Complement activation fragment Bb in early pregnancy and spontaneous preterm birthThe immune system and cardiac repair.The complement inhibitor FUT-175 suppresses T cell autoreactivity in experimental autoimmune encephalomyelitis.What does complement do in Alzheimer's disease? Old molecules with new insights.Residues 10-18 within the C5a receptor N terminus compose a binding domain for chemotaxis inhibitory protein of Staphylococcus aureus.Hepatitis B virus X protein protects hepatoma and hepatic cells from complement-dependent cytotoxicity by up-regulation of CD46.Prostaglandin E2 regulates the complement inhibitor CD55/decay-accelerating factor in colorectal cancer.Some morphological, growth, and genomic properties of human cells chronically infected with porcine endogenous retrovirus (PERV).Anti-inflammatory effects of C1-Inhibitor in porcine and human whole blood are independent of its protease inhibition activity.Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia.Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation.Site-specific disulfide capture of agonist and antagonist peptides on the C5a receptor.Hepatitis B virus X protein activates CD59 involving DNA binding and let-7i in protection of hepatoma and hepatic cells from complement attack.Increased inhibitory capacity of an anti-C5a complementary peptide following acetylation of N-terminal alanine.IL-10 protects monocytes and macrophages from complement-mediated lysis.Nafamostat mesilate inhibits the expression of HMGB1 in lipopolysaccharide-induced acute lung injury.
P2860
Q31144974-237A8F56-CFA2-41F7-955F-BF447F2C22F1Q33340963-776DA9C9-C52B-49F7-86EF-7847D7F9DD24Q33357218-8E2C746C-A646-4B9B-8E9F-0CC89305D262Q33417375-2FD4CCE4-D456-4501-A3AF-A4F09D42E8BCQ33422169-2B034FCB-EA5A-4EF0-A24E-0BA0AF1BD664Q33630434-7F233D8C-DF6A-469C-8EA4-A0E735A17609Q33687307-9B143EFC-18AD-4936-BA14-5AB04978F168Q34154819-7C84FB9A-85CF-4E11-A3A9-0498BCA3A587Q34699496-E7891C5B-F366-4DC0-9162-F29AD5055C02Q34731255-4FFC61BB-1394-461C-BAA3-817669F0404DQ35221722-458113B8-AD6B-4DD7-B07A-9DBA43B6C3E5Q36375663-899AEAA3-25CA-40EF-BB13-B5502CE85E45Q36980611-38AD3A08-2C5B-42CD-A54E-25BCA2A237E5Q37096652-B7A14FD4-EC6F-43C3-9005-8DB484C7FFC1Q37273745-B52FAABB-B60E-4AE2-A54F-854649958F52Q37368120-AA0F189C-8195-4F5F-99B4-7FDC15040430Q38334334-0666B45D-341E-4A12-9F3E-2B5DB34F4BBFQ39197950-C9161E70-94A5-40D3-9744-67030D2F9D37Q40497400-83A6A059-8D5F-4575-94D6-FC2FA2083999Q40618150-275BE64C-A09C-4A7C-A2E2-35351445D5D8Q41393053-71418B26-B94C-4093-9E78-2E46D1FF26EBQ42575209-594ED1F3-E060-45AC-876B-A16FF6CF06E1Q44738348-75204A12-24B9-4DD8-98D9-DB65EF9E4B96Q45154618-6CE81572-82EE-44C5-8D84-3803788691CBQ45365788-857518CB-EC38-45F8-9357-0982D5887700Q46738560-96AC42B7-0EF9-4189-A343-28E82CF970B3Q47961846-D7D2297D-3169-41DB-89C7-AB1CC7475C26Q48189013-9B9B6465-94C7-441D-AFFF-4DEC55F12D9E
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Targeting complement in therapy.
@ast
Targeting complement in therapy.
@en
Targeting complement in therapy.
@nl
type
label
Targeting complement in therapy.
@ast
Targeting complement in therapy.
@en
Targeting complement in therapy.
@nl
prefLabel
Targeting complement in therapy.
@ast
Targeting complement in therapy.
@en
Targeting complement in therapy.
@nl
P1476
Targeting complement in therapy.
@en
P2093
Kirschfink M
P304
P356
10.1034/J.1600-065X.2001.1800116.X
P577
2001-04-01T00:00:00Z